Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GFM-DACORAL-DLI
2019-003685-40Phase 2Active
- Sponsor
- Groupe Français des Myélodysplasies
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cedazuridine and decitabine in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), sponsored by Groupe Français des Myélodysplasies. Primary endpoint: DFS at 1 year post transplant. Started Nov 2020; status: active.
02
Drugs
cedazuridinedecitabine
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2019-003685-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003685-40.